原發性膽汁性肝硬化是一種慢性肝病，會引起發炎、纖維化和膽管阻塞，導致肝臟內微小膽管的消失。自體免疫、感染和/或遺傳易感性都是原發性膽汁性肝硬化的可能原因。搔癢、骨質疏鬆、高血膽固醇、脂肪和脂溶性維生素吸收不良是原發性膽汁性肝硬化的症狀，可發展為肝腫大和脾腫大色素沉著、黃疸、乾燥症或凱-弗環。原發性膽汁性肝硬化會隨著時間的推移而發展，最終可能導致肝臟完全停止功能。
Frequently Asked Questions
The market is segmented based on Segmentation, By Diagnosis (Imaging Tests, Blood Tests, Others), Treatment Type (Liver Transplantation, Drug Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2032
.
The Global Primary Biliary Cholangitis Market size was valued at USD 1.05 USD Billion in 2024.
The Global Primary Biliary Cholangitis Market is projected to grow at a CAGR of 10.5% during the forecast period of 2025 to 2032.
The major players operating in the market include F. Hoffmann-La Roche Ltd. , Mylan N.V. , Teva Pharmaceutical Industries Ltd. , Sanofi , Pfizer Inc. , GlaxoSmithKline plc , Novartis AG , Merck &, Co.Inc. , Allergan , AstraZeneca , Johnson &, Johnson Private Limited , Hikma Pharmaceuticals PLC , Bristol-Myers Squibb Company , Bayer AG , Boehringer Ingelheim International GmbH. , Dr. Reddy&rsquo,s Laboratories Ltd. , Gilead SciencesInc. , Amgen Inc. , Eli Lilly and Company , AbbVie Inc. , Lupin , Allergan .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
